Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Capecitabine in Adjuvant TNBC with TLS
NCT06313463Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2031
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Mar 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06313463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313463.